-+ 0.00%
-+ 0.00%
-+ 0.00%

Blau Farmaceutica publishes transcript of 2Q26 earnings call

PUBT·08/14/2026 15:25:43
Listen to the news
Blau Farmaceutica publishes transcript of 2Q26 earnings call
  • Blau held its 2Q26 earnings call with CEO Marcelo Hahn, CFO/DRI Douglas Rodrigues, and IR head Matheus Fujisawa.
  • 1H26 net revenue rose 10%; recurring EBITDA margin reached 25%; free cash flow after capex totaled 70 million, including 81 million in 2Q.
  • Management expects faster 2H growth on new production lines and easier comparisons; gross margin seen sustainable around 42% through 2026.
  • Approval for new production lines remains delayed by local health surveillance; inventory built for launch is awaiting clearance, constraining sales.
  • Full-year capex guided slightly below planned EBITDA; management cited BRL 400-450 million, led by pembrolizumab clinical study and Pernambuco packaging line.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blau Farmaceutica SA published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.